Products
Domagrozumab Biosimilar Monoclonal Antibody (Myostatin) for Research
Pre-Made Domagrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-151-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Domagrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody |
| INN Name | Domagrozumab |
| Target | GDF-8 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 5f3h:EF:GH:AB:CD |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Kennedy Krieger Institute;Pfizer |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | na |
About target - MSTN
1. Protein Growth/differentiation factor 8
2. Gene MSTN
3. Organism Homo sapiens (Human)
Function
Acts specifically as a negative regulator of skeletal muscle growth.
